If you are looking into psychedelic-assisted treatment in Estonia — for yourself or for someone close to you — there is in July 2026 exactly one route you can act on, and it is private. Esketamine is a registered medicine here, but we could not confirm any public funding for it, so access runs through a self-pay clinic in Tallinn with unusually transparent prices. Everything else — psilocybin, MDMA — is research-only. This guide covers who qualifies, how to start, what it costs, and what remains unverified; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine nasal spray) is registered in the Estonian medicines register for adults whose depression has not responded to at least two antidepressants, and for rapid short-term treatment of a psychiatric emergency. We found no confirmed Tervisekassa (health insurance fund) coverage, so the practical route is private: Marienthali Kliinik (MPPK) in Tallinn provides esketamine under psychiatric supervision at published prices — €130 per intravenous session, €590 for a two-dose or €820 for a three-dose intranasal session — with a doctor's referral required. Psilocybin and MDMA remain research-only.
At a glance
| Route | Substance | Status in Estonia | Who qualifies | Cost |
|---|---|---|---|---|
| Private esketamine | Esketamine (IV or nasal spray) | Registered medicine; offered privately at MPPK in Tallinn | Clinic screening: depression unresponsive to at least two antidepressants, or a severe episode needing rapid intervention; doctor's referral required | €130 per IV session (5-pack −20%); €590–820 per intranasal session |
| Reimbursed esketamine | Esketamine (Spravato) | Not confirmed — 2021 Tervisekassa assessment, no coverage found | — | — |
| Psilocybin therapy | Psilocybin | Research only | — | — |
| MDMA therapy | MDMA | Research only | — | — |
| Clinical trials | Psilocybin, MDMA, ketamine | No Estonian site in our tracked registry data | Study-specific criteria | Free |
How Estonia compares across the continent: Europe-wide reimbursement map.
Spravato in Estonia: registered, but no confirmed public route
Intranasal esketamine (Spravato) is registered in the Estonian medicines register for use with an oral antidepressant in adults who have not responded to at least two different antidepressants in the current moderate-to-severe episode, and as short-term acute treatment where a doctor judges the depressive symptoms a psychiatric emergency (MPPK; Ravimiamet register). Registration, however, is not access: Tervisekassa assessed an application to add intranasal esketamine to the public health-service list in 2021, and we have found no evidence that public coverage followed — the clinics offering the treatment price it as a fully self-pay service. If your budget is the constraint, our cost guide puts the numbers in European context.
Private esketamine at Marienthali Kliinik: the route that works
Marienthali Kliinik (MPPK), a licensed mental-health clinic at Kotka 12 in Tallinn, is the named Estonian provider of esketamine treatment. The clinic holds a Tervisekassa contract for parts of its ordinary psychiatric care, but esketamine sits on the paid price list.
Who qualifies. The clinic's published indication mirrors the registered one: depression that has not improved sufficiently on conventional antidepressants, or a severe episode needing rapid intervention. Contraindications include hypersensitivity and serious cardiovascular disease; the prescribing psychiatrist reviews your medicines for interactions. A doctor's referral is a precondition for esketamine treatment (MPPK price list).
How to start. Book a mental-health nurse appointment at the clinic and say you want to discuss esketamine. The nurse assesses your state and books you to a psychiatrist, who checks indications and contraindications; if treatment goes ahead you sign a written treatment contract and agree a plan — typically one to three sessions weekly for up to four weeks, then adjusted by response. A session, including assessment, dosing and observation, takes about two hours, with blood pressure monitored and a companion recommended for the trip home.
Cost. Prices are published: intravenous esketamine costs €130 per session (a five-session package is discounted 20 per cent); intranasal administration costs €590 for two doses or €820 for three doses per session. Around that sit the nurse visit (€60), first psychiatric appointment (€165) and repeat visits (price list). To see what is listed for Estonia, browse providers in Estonia.
What we don't know yet
An honest list of the gaps in our verification, as of 30 July 2026:
- Whether Spravato is actively marketed in Estonia. The registration exists, but we could not confirm routine pharmacy distribution of the branded spray, and MPPK's IV pricing suggests generic esketamine plays a role.
- Whether Tervisekassa ever pays. We found the 2021 assessment but no coverage decision, and no case-by-case exception route we can document.
- Other providers. MPPK is the only Estonian clinic we have verified; others may exist.
- Waiting times. The clinic publishes prices but not queue lengths.
Psilocybin and MDMA: research only
Psilocybin and MDMA remain controlled substances in Estonia with no medical-access route (Psychedelic Alpha tracker), and our tracked registry data shows no Estonian psychedelic trial site. The realistic option is a trial elsewhere in Europe — our trials guide explains how to search. Anyone offering psilocybin or MDMA therapy commercially in Estonia today is operating illegally.
What to expect in treatment
Whichever route you take, the shape of care is similar and worth picturing in advance. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; dissociation and a temporary rise in blood pressure are expected and settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction is typically more frequent at first and then tapers based on measured response, always combined with a continuing oral antidepressant.
A ketamine infusion is usually given intravenously over about 40–60 minutes with the same vital-sign monitoring and a recovery period afterwards; KAP programs wrap the dosing in preparation and integration sessions with a therapist. Where a legal psychedelic-therapy route exists (a compassionate-use programme, a regulated PAT programme or a clinical trial — availability differs by country), dosing days are long and closely supervised — two trained professionals including a physician stay with you — and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
- A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Substance-use concerns, particularly patterns of compulsive use.
A responsible provider screens for all of these before the first dose. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Germany.
Frequently asked questions
Does Tervisekassa cover esketamine treatment?
Not as far as we could confirm. An application to add intranasal esketamine to the service list was assessed in 2021, but the treatment is offered today as a self-pay service, and we found no coverage decision. Verify directly with Tervisekassa if your situation may warrant an exception.
How much does esketamine treatment cost in Estonia?
At MPPK: €130 per intravenous session (five-session package −20 per cent), €590 per two-dose or €820 per three-dose intranasal session, plus consultation fees — €60 for the nurse visit and €165 for the first psychiatric appointment. A multi-week course is standard, so budget for a series, not a single visit.
Do I need a referral?
Yes — the clinic states that a doctor's referral is a precondition for esketamine treatment. A letter from your GP or previous psychiatrist summarising your condition and medication history also speeds up the intake.
Can I get psilocybin or MDMA therapy in Estonia?
No. Both are research-only, no Estonian trial is in our tracked data, and no legal clinical route exists. Watch the registries or consider trial sites elsewhere in Europe.
Sources
- MPPK — Marienthali Kliinik: Treatment with esketamine (indications, procedure, intake)
- MPPK — Marienthali Kliinik: Price list (esketamine sessions, consultations; referral precondition)
- Tervisekassa: Assessment of intranasal esketamine for the health-service list (2021)
- Ravimiregister — Estonian medicines register
- EMA: Spravato (esketamine) EPAR
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- ClinicalTrials.gov
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, prices and coverage rules can change; always verify current requirements with Ravimiamet, Tervisekassa, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.